Migraine : Evolution of a Common Disorder

Authors

  • Rohit Chaudhary  School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
  • Rohan Saini  School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
  • Robin Singh Rawat  School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
  • Rajat Bachhas  School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
  • Raphael Majani  School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
  • Mrs. Hema Arya  Assistant Professor, Sharda University, Greater Noida, Uttar Pradesh, India

DOI:

https://doi.org/10.32628/IJSRST229399

Keywords:

MIGRAINE, CSD, MO, Vasospasm, Ion Calcium Channel.

Abstract

MIGRAINE is a common, chronic, incapacitating neurovascular disorder, characterized by attacks of severe headache, autonomic nervous system dysfunction, and in some patients, an aura involving neurologic symptoms. In one-third of patients the headache is preceded by transient neurological symptoms that are most frequently visual but may involve other senses and speech [migraine with aura (MA)]. Migraine is extremely prevalent [affecting 17% of females and 8% of men], very expensive ($18.5 billion Euros per year in Europe], and disabling [one of the World Health Organization's top 20 most disabling disorders]. It is consequently a public fitness hassle of exceptional effect on each the man or woman and society. Most migraine assaults begin with inside the mind, as advised through (a) the premonitory signs (e.g., issue with speech and reading, expanded emotionality, sensory hypersensitive reaction) that during many sufferers are exceptionally predictive of the attack, even though such signs arise as much as 12 h earlier than the attack, and through (b) the character of a few usual migraine triggers which includes stress, sleep deprivation, oversleeping, hunger, and extended sensory stimulation. Psychophysical and neurophysiological research have supplied clean proof that with inside the duration among assaults migraines display hypersensitive reaction to sensory stimuli and odd processing of sensory information, characterized through expanded amplitudes and decreased habituation of evoked and event-associated potentials. It is usually believed that migraine headache relies upon at the activation and sensitization of the trigeminovascular ache pathway and that cortical spreading depression (CSD) is the neurophysiological correlate of migraine aura. CSD may be precipitated in animals through focal stimulation of the cerebral cortex and includes a slowly propagating (2–6 mm min−1) wave of robust neuronal and glial depolarization; the mechanisms of initiation and propagation of CSD continue to be unclear. The mechanisms of the number one mind dysfunction(s) main to the onset of a migraine attack, to CSD susceptibility, and to episodic activation of the trigeminovascular ache pathway continue to be in large part unknown and the predominant open problem with inside the neurobiology of migraine.

References

  1. Goads by, P.J., Lipton, R.B. and Ferrari, M.D., 2002. Migraine—current understanding and treatment. New England journal of medicine, 346(4), pp.257-270.
  2. May, A. and Goads by, P.J., 1999. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. Journal of Cerebral Blood Flow & Metabolism, 19(2), pp.115-127.19. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic Migraine and episodic ataxia type-2 are caused by mutations in the Ca2+Channel gene CACNL1A4. Cell 1996; 87:543-52.
  3. Terwindt, G.M., Ophoff, R.A., Van Eijk, R., Vergouwe, M.N., Haan, J., Frants, R.A., Sandkuijl, L.A. and Ferrari, M.D., 2001. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology, 56(8), pp.1028-1032.
  4. Schiffer, J., Avidan, D. and Rapp, A., 1985. Posttraumatic meningioma. Neurosurgery, 17(1), pp.84-87.
  5. Goadsby, P.J., 2001. Migraine, aura, and cortical spreading depression: why are we still talking about it?. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 49(1), pp.4-6.
  6. Viirre, E.S. and Baloh, R.W., 1996. Migraine as a cause of sudden hearing loss. Headache: The Journal of Head and Face Pain, 36(1), pp.24-28.
  7. Lauritzen M. Pathophysiology of the migraine aura: the spreading depression theory. Brain. 1994 Feb 1;117(1):199-210.
  8. Hupp, S.L., Kline, L.B. and Corbett, J.J., 1989. Visual disturbances of migraine. Survey of ophthalmology, 33(4), pp.221-236.
  9. Tippin, J., Corbett, J.J., Kerber, R.E., Schroeder, E. and Thompson, H.S., 1989. Amaurosisfugax and ocular infarction in adolescents and young adults. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 26(1), pp.69-77.
  10. Winterkorn, J., Kupersmith, M.J., Wirtschafter, J.D. and Forman, S., 1993. Treatment of vasospastic amaurosisfugax with calcium-channel blockers. New England Journal of Medicine, 329(6), pp.396-398.
  11. Perez‐Reyes, E. and Schneider, T., 1994. Calcium channels: structure, function, and classification. Drug development research, 33(3), pp.295-318.
  12. Moskowitz, M.A., 1990. Basic mechanisms in vascular headache. Neurologic clinics, 8(4), pp.801-815.
  13. Baloh, R.W., 1997. Neurotology of migraine. Headache: The Journal of Head and Face Pain, 37(10), pp.615-621.
  14. Raskin, N.H., 1993. Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale. Neurology, 43(6 Suppl 3), pp.S39-42.
  15. Welch, K.M.A., 1993. Drug therapy of migraine. New England Journal of Medicine, 329(20), pp.1476-1483.
  16. Diener, H.C. and antagonist RPR100893, S.P., 1996. 201 is not effective in human migraine attacks. In Proceedings of the VIth International Headache Seminar. New York: Lippincott-Raven.
  17. Goldstein, D.J., Wang, O., Saper, J.R., Stoltz, R., Silberstein, S.D. and Mathew, N.T., 1997. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia, 17(7), pp.785-790.
  18. Goldstein, D.J., Offen, W.W., Klein, E.G., Phebus, L.A., Hipskind, P., Johnson, K.W. and Ryan Jr, R.E., 2001. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia, 21(2), pp.102-106.
  19. Norman, B., Panebianco, D. and Block, G.A., 1998. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia, 18(407), pp.1092-1093.
  20. Connor, H.E., Bertin, L., Gillies, S., Beattie, D.T. and Ward, P., 1998. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia, 18, p.392.134. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996;67:375-8.
  21. Data, J., Britch, K., Westergaard, N., Weihnuller, F., Harris, S., Swarz, H., Silberstein, S., Goldstein, J., Ryan, R., Saper, J. and Londborg, P., 1998. A double-blind study of ganaxolone in the acute treatment of migraine headaches with or without an aura in premenopausal females. Headache, 38, p.380.
  22. Roon, K.I., Olesen, J., Diener, H.A., Ellis, P., Hettiarachchi, J., Poole, P.H., Christianssen, I., Kleinermans, D., Kok, J.G. and Ferrari, M.D., 2000. No acute antimigraine efficacy of CP‐122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double‐blind, placebo‐controlled clinical trials. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 47(2), pp.238-241.
  23. Earl, N.L., McDonald, S.A. and Lowy, M.T., 1999. 4991W93 Investigator Group. Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia, 19, p.357.
  24. Ramadan, N., Sang, C., Chappell, A., Vandenhende, F., Johnson, K., Phebus, L., Bleakman, D., Ornstein, P., Arnold, B., Freitag, F. and Smith, T., 2001. IV LY293558, an AMPA/KA receptor antagonist, is effective in migraine. Cephalalgia, 21, pp.267-8.
  25. Goadsby, P.J., Hoskin, K.L., Storer, R.J., Edvinsson, L. and Connor, H.E., 2001. Inhibitory effects of adenosine A1 agonists on the cat trigeminovascular system: a new target for anti-migraine drugs. Cephalalgia,21,p.352.

Downloads

Published

2022-06-30

Issue

Section

Research Articles

How to Cite

[1]
Rohit Chaudhary, Rohan Saini, Robin Singh Rawat, Rajat Bachhas, Raphael Majani, Mrs. Hema Arya "Migraine : Evolution of a Common Disorder" International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011,Volume 9, Issue 3, pp.520-529, May-June-2022. Available at doi : https://doi.org/10.32628/IJSRST229399